CD274 and non-small cell lung carcinoma: <b>Methods:</b> We conducted a retrospective, single-center real-world analysis of patients with metastatic NSCLC and high PD-L1 expression who initiated first-line immune checkpoint inhibitor monotherapy between May 2024 and January 2025.